Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy

References

• Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, . Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, . Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186–95.
   PubMed Web of Science ®Google Scholar
• Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986–93.
   PubMed Web of Science ®Google Scholar
• Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, . Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787–94.
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896–1905.
   PubMed Web of Science ®Google Scholar
• Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, . Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006;80:8807–19.
   PubMed Web of Science ®Google Scholar
• Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, . Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006;43:60–4.
   PubMed Web of Science ®Google Scholar
• Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, González-Lahoz J, . Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004;74:21–8.
   PubMed Web of Science ®Google Scholar
• Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, . A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. J Med Virol 2006;78:1312–7.
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Reynes J, Yerly S, Ktorza N, Segondy M, Piot JC, . Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 2004;18:1340–2.
   PubMed Web of Science ®Google Scholar
• Poveda E, Rodes B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005;34:295–301.
   PubMed Web of Science ®Google Scholar
• Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, . Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;5:714–22.
   Google Scholar
• Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, . Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007;195:387–91.
   PubMed Web of Science ®Google Scholar
• Hanna SL, Yang C, Owen SM, Lal RB. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide. AIDS 2002;16:1603–8.
   PubMedGoogle Scholar
• Si-Mohamed A, Piketty C, Tisserand P, LeGoff J, Weiss L, Charpentier C, . Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr 2007;44:1–5.
   PubMed Web of Science ®Google Scholar
• Thompson JD, Higgins DG, Gibson TJ. Clustal W. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673–80.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, . Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005;192:1537–44.
   PubMed Web of Science ®Google Scholar
• Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, . Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005;410:236–42.
   Google Scholar
• Eron JJ Jr, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, . Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004;37:1581–3.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555–70.
   PubMed Web of Science ®Google Scholar
• Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. AIDS Res Hum Retroviruses 2007;23:1078–82.
   PubMed Web of Science ®Google Scholar
• Marconi V, Bonhoeffer S, Paredes R, Lu J, Hoh R, Martin JN, . Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. J Acquir Immune Defic Syndr 2008;48:572–6.
   PubMed Web of Science ®Google Scholar
• Cabrera C, Marfil S, Garcia E, Martinez-Picado J, Bonjoch A, Bofill M, . Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006;20:2075–80.
   PubMed Web of Science ®Google Scholar
• Trabaud MA, Cotte L, Labernardiere JL, Lebel-Binay S, Icard V, Tardy JC, . Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo. J Acquir Immune Defic Syndr 2007;46:34–44.
   Web of Science ®Google Scholar
• Chibo D, Roth N, Roulet V, Skrabal K, Gooey M, Carolan L, . Virological fitness of HIV in patients with resistance to enfuvirtide. AIDS 2007;21:1974–7.
   PubMed Web of Science ®Google Scholar
• Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, . Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004;48:3253–9.
   PubMed Web of Science ®Google Scholar